Published in Scand J Urol on January 10, 2013
Survival up to 5-15 years in young women following genital sparing radical cystectomy and neobladder: oncological outcome and quality of life. Single-surgeon and single-institution experience. Cent European J Urol (2015) 0.88
Sparing radical cystectomy - How much is enough? Cent European J Urol (2015) 0.75
Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol (2004) 3.15
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
Gender-related fetal development of the internal urethral sphincter. Urology (2013) 2.61
Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int (2008) 2.60
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol (2010) 2.47
Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection. J Urol (2002) 2.37
Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc Natl Acad Sci U S A (2009) 2.33
Combination of lidocaine suppository and periprostatic nerve block during transrectal prostate biopsy: a prospective randomized trial. Int J Urol (2014) 1.98
Early diagnosis and straight forward surgery of an asymptomatic primary angiosarcoma of the kidney led to long-term survival. Int J Urol (2006) 1.92
Evaluation of the PI-RADS scoring system for mpMRI of the prostate: a whole-mount step-section analysis. World J Urol (2014) 1.78
Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem (2005) 1.73
Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology (2007) 1.69
Robotic-assisted laparoscopic partial nephrectomy: surgical technique and clinical outcomes at 1 year. BJU Int (2008) 1.68
Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate (2005) 1.68
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol (2008) 1.68
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol (2003) 1.67
Robotic Anderson-Hynes pyeloplasty: 5-year experience of one centre. BJU Int (2007) 1.67
Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients. Eur Urol (2012) 1.56
Safer transurethral resection of the prostate: coagulating intermittent cutting reduces hemostatic complications. J Urol (2004) 1.54
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology (2003) 1.46
Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol (2004) 1.44
Real-time elastography for detecting prostate cancer: preliminary experience. BJU Int (2007) 1.44
Endoscopic application of dextranomer/hyaluronic acid copolymer in the treatment of vesico-ureteric reflux after renal transplantation. BJU Int (2010) 1.44
Model-based optimal design of polymer-coated chemical sensors. Anal Chem (2003) 1.43
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol (2003) 1.40
Late penile metastasis from primary bladder carcinoma. Urology (2003) 1.32
Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol (2004) 1.31
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer (2008) 1.30
Factors contributing to the racial differences in prostate cancer mortality. BJU Int (2005) 1.26
Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol (2006) 1.21
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging (2015) 1.18
Comparison of sonoelastography guided biopsy with systematic biopsy: impact on prostate cancer detection. Eur Radiol (2007) 1.17
The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate (2011) 1.13
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol (2010) 1.12
The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate (2010) 1.10
Long-term follow up of renal anastomosing hemangioma mimicking renal angiosarcoma. Int J Urol (2014) 1.09
Androgen receptors in prostate cancer. J Urol (2003) 1.07
Real-time sonoelastography for the evaluation of testicular lesions. Radiology (2012) 1.05
The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer. J Urol (2006) 1.05
Occurrence of polyorchidism in a young man. Urology (2002) 1.05
The proximal neurovascular plate and the tri-zonal neural architecture around the prostate gland: importance in the athermal robotic technique of nerve-sparing prostatectomy. BJU Int (2006) 1.03
Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer. J Urol (2008) 1.02
Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mL. BJU Int (2008) 1.00
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol (2011) 1.00
Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int (2006) 0.99
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J Steroid Biochem Mol Biol (2013) 0.99
Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate (2003) 0.99
Status of transrectal ultrasound imaging of the prostate. J Endourol (2010) 0.97
Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health (2011) 0.96
Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol (2005) 0.96
Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2010) 0.96
Value of contrast-enhanced ultrasound and elastography in imaging of prostate cancer. Curr Opin Urol (2007) 0.95
Single-stage dorsal inlay split-skin graft for salvage anterior urethral reconstruction. BJU Int (2008) 0.94
Ultrasound of the prostate. Cancer Imaging (2010) 0.94
Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2012) 0.94
Mitochondrial haplogroups and control region polymorphisms are not associated with prostate cancer in Middle European Caucasians. PLoS One (2009) 0.94
A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detection. Prostate (2007) 0.92
Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project. Urology (2005) 0.92
Comparative efficiency of contrast-enhanced colour Doppler ultrasound targeted versus systematic biopsy for prostate cancer detection. Eur Radiol (2010) 0.92
Fluorescence in situ hybridization for detecting upper urinary tract tumors--a preliminary report. Urology (2007) 0.92
Contrast-enhanced ultrasonography using cadence-contrast pulse sequencing technology for targeted biopsy of the prostate. BJU Int (2008) 0.92
Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease? BJU Int (2006) 0.91
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proc Natl Acad Sci U S A (2012) 0.91
Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. Adv Exp Med Biol (2008) 0.91
Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology (2003) 0.91
The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels. BJU Int (2005) 0.91
Cancer control and the preservation of neurovascular tissue: how to meet competing goals during robotic radical prostatectomy. BJU Int (2008) 0.90
Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening population. Prostate (2004) 0.90
The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Prostate (2006) 0.90
Quantitative measurement of the androgen receptor in prepuces of boys with and without hypospadias. BJU Int (2013) 0.90
Periprostatic administration of local anesthesia during transrectal ultrasound-guided biopsy of the prostate: a randomized, double-blind, placebo-controlled study. Urology (2003) 0.90
Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol (2006) 0.90
Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the tyrol screening project. Eur Urol (2005) 0.89
The value of three-dimensional transrectal ultrasonography in staging prostate cancer. BJU Int (2007) 0.89
Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int (2005) 0.89
Comparison of real-time sonoelastography with T2-weighted endorectal magnetic resonance imaging for prostate cancer detection. J Ultrasound Med (2011) 0.89
Serum-autoantibodies for discovery of prostate cancer specific biomarkers. Prostate (2011) 0.88
Molecular cytogenetic analysis of human spermatocytic seminomas. J Pathol (2004) 0.88
Long-term results of laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testicular cancer. J Endourol (2007) 0.87
(68)Ga-PSMA ligand PET versus (18)F-NaF PET: evaluation of response to (223)Ra therapy in a prostate cancer patient. Eur J Nucl Med Mol Imaging (2014) 0.87
Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference? BJU Int (2008) 0.87
Comparison of complications from radical cystectomy between old-old versus oldest-old patients. Urol Int (2014) 0.87
Tumor recurrence in the remnant urothelium of females undergoing radical cystectomy for transitional cell carcinoma of the bladder: long-term results from a single center. J Urol (2006) 0.86
Long-term morbidity and mortality of transurethral prostatectomy: a 10-year follow-up. Prostate (2004) 0.85
Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens. Prostate (2003) 0.85
Perforation during TUR of bladder tumours influences the natural history of superficial bladder cancer. World J Urol (2013) 0.85